- Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execUli Stilz has been trotting the globe this year to talk about the future of biotech and bridge an increasingly international industry. He was in Japan this week,Endpoints · 1mo ago↗ source
- Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?<figure><div><img src="https://imgproxy.divecdn.com/xbHcBuJpB2jn4XdBnacn9EL1qH4IPhhgp3V92WERlvI/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjYtMDYtMDNfYXRfM…BioPharma Dive · 1mo ago↗ source
- Otsuka touts new IgAN evidence as it seeks full approval for VoyxactOtsuka Pharmaceutical reported new evidence on Thursday that it thinks will help support a full approval for its monoclonal antibody Voyxact in a chronic autoimmune disease that affects the kidneys…